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Abstract 
Introduction: Research objectives of present study were to examine sex and age-related specifics of diabetic 
retinopathy according to the therapy approach and duration of diabetes mellitus. The study also aimed to 
determine the association between the presence of diabetic retinopathy and diabetes duration as a prognostic 
factor of retinopathy progression in such patients.  
Materials and Methods: The study was designed as a retrospective study and included 289 patients with 
diabetic retinopathy, who were treated at the Department of Ophthalmology of the General Hospital “Dr. Josip 
Benčević” in Slavonski Brod during the period from 2019 to 2020. 
Results: 176 patients were treated with oral antidiabetic drugs (OAD), while 113 patients were insulin-
dependent. The median age of patients treated with OAD was 77 years. Diabetic retinopathy was present in 35 
(19.9%) patients, of whom 33 (18.8%) had non-proliferative diabetic retinopathy, while 2 patients (1.1%) had 
proliferative diabetic retinopathy. The median age of the insulin-dependent patients was 79 years. Diabetic 
retinopathy was present in 54 patients (47.8%), non-proliferative diabetic retinopathy was diagnosed in 51 
patients (45.1%), while proliferative diabetic retinopathy was diagnosed in only 3 (2.7%) patients. There was a 
significant difference between the presence of diabetic retinopathy and diabetes duration (P<0.001), as well as 
between the therapy approach and diabetes duration (⍺<0.001). 
Conclusion: Various hypotheses have been proposed to explain the worsening of diabetic retinopathy, and we 
assume that the therapy approach, duration of diabetes and HbA1c have a significant role in retinopathy 
progression. Hereby, we emphasize that, although there have been significant advances, there is still a pressing 
need for a better understanding of a new therapeutic modality, new tools for identifying high-risk patients and 
continued monitoring in order to intervene effectively before vision loss occurs. Further research is needed to 
identify and implement the best practices to increase diabetic eye screening rates in the long term. 
(Bardak A, Kovacevic S, Kovacevic B, Vukovic Arar Z, Sekelj S, Nizic D, Bosnic Z. Association Between Diverse 
Diabetic Treatments and Duration of Diabetes Mellitus According to Progression of Diabetic Retinopathy: 
Experience From a Small Regional Hospital. SEEMEDJ 2021; 5(1); 65-74) 
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Introduction 
Diabetic retinopathy (DR) is one of the most 
frequent complications of diabetes mellitus and 
it remains a leading cause of vision loss globally. 
Its aetiology and pathology have been 
extensively studied for half a century, but 
unfortunately, there are few therapeutic options 
and prevention of progression is still the ultimate 
goal. It affects an estimated 126.6 million people 
worldwide and it is expected to increase rapidly 
in the future (1).  
Even though many studies, such as The 
Diabetes Control and Complications Trial (DCCT) 
and The United Kingdom Prospective Diabetes 
Study (UKPDS), have confirmed a strong 
relationship between chronic hyperglycaemia 
and the development and progression of 
diabetic retinopathy, there is a lack of 
understanding of the underlying mechanism 
leading to the development of microvascular 
damage (2, 3). According to the WHO, diabetic 
retinopathy is described as a major cause of 5% 
of vision loss in the developed world and its 
prevalence is expected to double by 2030. As 
stated by the American Diabetes Association, 
21% of patients with diabetes mellitus have 
diabetic retinopathy at the moment of first 
diagnosis of diabetes, and more than 60% of 
patients develop DR within 20 years after the 
diagnosis (4). Microvascular damage slowly 
accumulates in the retinal blood vessels, leading 
to retinal ischemia, higher retinal permeability, 
neovascularization and macular oedema, finally 
resulting in complete vision loss (5-7). The risk of 
development and progression of diabetic 
retinopathy is closely associated with the type 
and duration of diabetes, blood sugar levels, 
blood pressure levels, proteinuria and possibly 
hyperlipidaemia (8). Recent studies suggest that 
apolipoproteins, inflammatory factors and 
genetic risk factors could also play a role in the 
development and progression of diabetic 
retinopathy (9). An ideal model of screening 
tools for diabetic retinopathy is based on an 
annual examination of visual acuity and the eye 
fundus in all diabetic patients. Adults with type 2 
diabetes should undergo an eye screening test 
at the time of diabetes diagnosis. Annual eye 
exams are recommended, but if there is no 
evidence of diabetic retinopathy, eye screening 
every two years thereafter may be considered 
(10). 
Family medicine physicians have adequate 
knowledge and awareness of diabetic eye 
screening guidelines. However, they encounter 
barriers in ensuring that patients undergo 
screening due to burdensome and complex 
tasks they are required to complete during the 
patient’s average 15-20-minute visit to the clinic, 
as well as due to a lack of access to the patients’ 
eye exam records. Patients should undergo 
follow-ups by an experienced ophthalmologist 
using precise eye fundus imaging methods at 
least once a year. Examination of the eye fundus 
completed with fluorescein angiography make a 
gold standard in retinopathy diagnosis and 
classification (11). 
Research objectives of the present study were 
to examine sex and age-related specifics of 
diabetic retinopathy according to the therapy 
approach, duration of diabetes mellitus, as well 
as accompanying comorbidities. The study also 
aimed to determine the association between the 
presence of diabetic retinopathy, diabetes 
duration and HbA1c as prognostic factors of 
retinopathy progression in such patients. 
Materials and Methods  
The retrospective study was conducted on 289 
patients treated at the Department of 
Ophthalmology of the General Hospital “Dr. 
Josip Benčević” in Slavonski Brod, Croatia during 
the period from 2019 to 2020. The data were 
collected from the medical records kept by the 
Department of Ophthalmology of the General 
Hospital “Dr. Josip Benčević”. The inclusion 
criteria were the presence of diabetes mellitus 
and biomicroscope presence of diabetic 
retinopathy. All procedures performed in this 
study were in accordance with the ethical 
standards of the institutional and/or national 
research committee and with the 1964 
Declaration of Helsinki and its later amendments 
or comparable ethical standards. 
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Statistical methods 
Categorical data were presented by absolute 
frequency and percentage, while numerical data 
were presented by the median, minimum, 
maximum and interquartile range. Differences in 
nominal variables were tested by the Fisher’s 
exact test, while differences in numeric variables 
were tested by the Mann–Whitney U Test 
because of deviations from the normal 
distribution. All P-values were two-sided. The 
level of significance was set at α= 0.05. IBM 
SPSS Statistics was used for the statistical 
analysis (IBM Corp. Released 2015. IBM SPSS 
Statistics for Macintosh, Version 23.0. Armonk, 
NY: IBM Corp.). 
Results 
This study was conducted on 289 patients, who 
were divided into two groups based on the 
therapy approach. The first group (N=176) was 
treated with oral antidiabetic drugs (OAD), while 
the second group of patients (N=113) was insulin-
dependent (Table 1 and Table 2). 
Table 1. Characteristics of patients (N = 176) treated with oral antidiabetic drugs 
Frequency Percentage 
Gender   
Male 72 40.9% 
Female 104 59.1% 
Smoking   
Yes 5 2.8% 
No 171 97.2% 
Alcohol consumption   
Yes 2 1.1% 
No 174 98.9% 
Hypertension   
Yes 160 90.9% 
No 16 9.1% 
Diabetic retinopathy   
Yes 35 19.9% 
No 141 80.1% 
Non-proliferative diabetic retinopathy   
Yes 33 18.8% 
No 143 81.3% 
Proliferative diabetic retinopathy   
Yes 2 1.1% 
No 174 98.9% 
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Table 2. Characteristics of insulin-dependent patients (N=113) 
Frequency Percentage 
Gender   
Male 55 48.7 % 
Female 58 51.3 % 
Smoking   
Yes 9 8.0 % 
No 104 92.0 % 
Alcohol consumption   
Yes 2 1.8 % 
No 111 98.2 % 
Hypertension   
Yes 101 89.4 % 
No 12 10.6 % 
Diabetic retinopathy   
Yes 54 47.8 % 
No 59 52.2 % 
Non-proliferative diabetic retinopathy   
Yes 51 45.1 % 
No 62 54.9 % 
Proliferative diabetic retinopathy   
Yes 3 2.7 % 
No 110 97.3 % 
 
The median age of patients treated with OAD 
was 77 years (interquartile range of 71-84), with a 
minimum age of 50 years and a maximum age of 
95 years. The median age of the insulin-
dependent patients was 79 years (interquartile 
range of 71-83), with a minimum age of 47 years 
and a maximum age of 96 years. Out of 176 
patients who received OAD, 35 (19.9%) had 
diabetic retinopathy, while 141 (80.1%) did not. A 
total of 113 patients were insulin-dependent, of 
whom 54 (47.8%) had diabetic retinopathy and 59 
(52.2%) did not (Table 3). The OAD group included 
72 male patients (40.9%) and 104 female patients 
(59.1%). Five patients (2.8%) were smokers and 171 
patients (97.2%) were non-smokers. Frequent 
alcohol consumption was reported by 2 patients 
(1.1%), while 174 patients (98.9%) did not consume 
alcohol frequently. Hypertension was diagnosed 
in 160 patients (90.9%), while 16 patients (9.1%) 
did not have hypertension. Diabetic retinopathy 
was present in 35 patients (19.9%), while 141 
patients (80.1%) were not diagnosed with 
diabetic retinopathy. Out of 176 patients, 33 
patients (18.8%) had non-proliferative diabetic 
retinopathy, while 2 patients (1.1%) had 
proliferative diabetic retinopathy (Table 1)
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Table 3. Characteristics of patients receiving oral antidiabetic drug therapy (OAD) or insulin 
depending on the presence of diabetic retinopathy 
 OAD Insulin Total P• 
Patients with diabetic retinopathy 35 (19.9) 54 (47.8) 89 (30.8) <0.001 
Patients without diabetic retinopathy 141 (80.1) 59 (52.2) 200 (69.2) <0.001 
Total 176 (100) 113 (100) 289 (100)  
Fisher’s exact test 
The insulin-dependent group consisted of 55 
men (48.7%) and 58 women (51.3%). Out of 113 
patients, 9 (8.0%) were smokers and 104 (92.0%) 
were non-smokers. Frequent alcohol 
consumption was reported by 2 patients (1.8%). 
Hypertension was diagnosed in 101 patients 
(89.4%), while 12 patients (10.6%) did not have 
hypertension. Diabetic retinopathy was present 
in 54 patients (47.8%), while 59 patients (52.2%) 
were not diagnosed with diabetic retinopathy. 
Non-proliferative diabetic retinopathy was 
diagnosed in 51 patients (45.1%), while the 
proliferative type was diagnosed in only 3 
patients (2.7%).  
The groups differed based on diabetes duration. 
Patients receiving OAD had a median duration of 
diabetes of 7 years (interquartile range of 4-12 
years), with a minimum duration of 6 months and 
a maximum duration of 35 years. A median 
duration of diabetes in the insulin-dependent 
patients was 12 years (interquartile range of 7-20 
years), with a minimum duration of 3 months and 
a maximum duration of 55 years. Patients 
diagnosed with diabetic retinopathy had a 
median duration of diabetes of 14 years 
(interquartile range of 8.5-20 years), with a 
minimum duration of 0 months and a maximum 
duration of 20 years. The patients without 
diabetic retinopathy had a median duration of 
diabetes of 7 years (interquartile range of 4-12 
years), with a minimum duration of 6 months and 
a maximum duration of 55 years (Figure 1).
 
Figure 1. Difference in diabetes duration distribution between patients receiving oral antidiabetic 
drugs and insulin (A) and between patients with and without diabetic retinopathy (B). p < 0.001 both 
in Figure 1A and Figure 1B. 
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Patients diagnosed with diabetic retinopathy 
had a median duration of diabetes of 14 years 
(interquartile range of 8.5-20 years), with a 
minimum duration of 0 months and a maximum 
duration of 20 years. On the other hand, the 
patients without diabetic retinopathy had a 
median duration of diabetes of 7 years 
(interquartile range of 4-12 years), with a 
minimum duration of 6 months and a maximum 
duration of 55 years.   
HbA1c concentrations were determined in the 
patients treated with OAD and insulin. The 
patients treated with OAD had a significantly 
lower median concentration of 6.3 mmol/L 
(interquartile range of 6.1-6.9), with a minimum 
concentration of 5.5 and a maximum 
concentration of 7.8 mmol/L. Patients treated 
with insulin had a median concentration of 7.6 
mmol/L (interquartile range of 6.6-8.9), with a 
minimum HbA1c concentration of 5.5 and a 
maximum concentration of 12.3 mmol/L (Figure 
2).
Figure 2. Difference in HbA1c concentration between patients receiving oral antidiabetic drugs and 
insulin (A) and between patients with and without diabetic retinopathy (B). p < 0.001 both in Figure 
2A and Figure 2B.  
 
Discussion 
Diabetic eye screening and treatment guidelines 
are part of the core curriculum for training eye 
care providers, but the current eye care provider 
workforce is insufficient to meet the increasing 
number of diabetic patients. According to 
epidemiological data, the number of diabetic 
patients is growing. These patients comprise a 
large share of eye care provider clinic time, but 
only one in 20 patients has vision-threatening 
diabetic eye disease. Our study included 289 
patients who suffered from type 2 DM. Patients 
were divided into two groups according to the 
therapy approach. There were more patients 
who used OAD. The majority of the patients 
using OAD were females who suffered from 
arterial hypertension, did not consume alcohol 
and did not smoke. Most of them had no signs of 
diabetic retinopathy and only two patients had 
confirmed proliferative diabetic retinopathy 
(Table 1). In contrast to them, there was a similar 
number of male and female patients who were 
insulin-dependent. Most of them suffered from 
arterial hypertension and half of them had 
confirmed DR. Only three insulin-dependent 
patients had proliferative DR. The insulin-
dependent patients had more cases of DR 
confirmed compared to patients who were 
taking OAD (Table 3). Despite a relatively high 
prevalence of DR in our study, our results are 
close to the prevalence of DR reported in the 
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Region-Specific Information (Europe) and 
worldwide (Table 3) (12). 
Some researchers have pointed out a higher 
prevalence of DR in patients treated with insulin, 
suggesting that insulin therapy may be 
associated with DR and DR severity when 
compared to the oral antidiabetic drug (OAD) 
therapy (13). On the other hand, another study, 
conducted by Gupta et al., has also shown a 
higher prevalence of DR among insulin users 
than in patients treated with OAD (52.9% vs 
16.3%), discussing how insulin therapy is often 
started later in the course of the disease, at a 
stage when glycaemic control is suboptimal for 
the subject. It was also argued that insulin is 
simply a marker of disease severity, rather than 
an independent risk factor for DR, suggesting 
that starting insulin therapy earlier in the course 
of the disease might be more beneficial in 
preventing the development of DR in the longer 
run (14). In the EURODIAB study, mild forms of 
non-prolferative diabetic retinopathy (NPDR) 
were recorded in 25.8%, moderate NPDR in 9.8%, 
and PDR in 10.6% of insulin-treated patients. The 
study included 3250 insulin-treated diabetic 
patients from 13 European diabetes centres, with 
a mean diabetes duration of 14.7 years. The 
major factors for vision loss are patient age, 
diabetes duration, glycosylated haemoglobin 
and the grade of retinopathy (15, 16). 
DM duration is a predictor of diabetic retinopathy 
(17). Patients with type 1 diabetes develop 
diabetic retinopathy within five years or less, and 
only occasionally later, i.e. 27% and 71-90% of 
patients with diabetes duration of 5-10 and >10 
years, respectively. At 20-30 years of diabetes 
duration, the incidence of diabetic retinopathy 
increases to 95%. Usually 30-50% of these 
patients develop proliferative diabetic 
retinopathy (PDR) (18). In our study, the patients 
receiving OAD had a median duration of 
diabetes of 7 years (interquartile range of 4-12 
years), while the median duration of diabetes in 
the insulin-dependent patients was 12 years 
(interquartile range of 7-20 years). The median 
age of the patients receiving OAD was 77 years 
(IQR of 71-84), while the median age of the 
patients treated with insulin was 79 years (IQR of 
71-83). There was a significant difference 
between the presence of diabetic retinopathy 
and diabetes duration (⍺<0.001) (Figure 1A). Thus, 
most of the patients were elderly persons with a 
comorbidity (e.g. arterial hypertension). Even 
though the prevalence of DM is relatively high 
among elderly patients, the incidence of DR and 
PDR in our study is close to the results of studies 
conducted in other European countries (12).  
There are several factors which could explain 
these observations, some of which are a 
relatively high quality of life in the last 10 years, 
newly designed OAD and combinations of OAD, 
free physical examinations twice or thrice a year 
and morphological characteristics of the eye 
structure in elderly persons (posterior vitreous 
detachment), resulting in slower progression of 
DR than that observed (19). 
Only a few participants in present study 
consumed alcohol, so alcohol can be excluded 
as a risk factor and is not directly associated with 
the presence or progression of diabetic 
retinopathy (Table 1 and Table 2). Our results are 
similar to the multicentric study by Lee CC et al., 
who investigated the association between 
alcohol consumption and diabetic retinopathy 
and deterioration of visual acuity in individuals 
with type 2 diabetes, concluding that alcohol 
consumption is associated with an increased risk 
of deterioration of visual acuity, but not with 
retinopathy in individuals with type 2 diabetes 
(20). The relationship between cigarette smoking 
and diabetic retinopathy was examined earlier 
and data suggest that there is no excess risk of 
retinopathy in smokers or ex-smokers when 
contrasted with those who have never smoked. 
Our study produced similar results due to the 
fact that a small number of participants 
consumed cigarettes (Table 1 and Table 2) (21). 
Landmark multi-centre, randomised controlled 
trials showed that early identification and proper 
treatment can prevent the risk of vision loss by 
90%, but fewer than 50% of people with diabetes 
in the USA follow diabetic eye screening 
guidelines and even lower screening rates (10-
20%) have been described (22). Once retinopathy 
is present, the duration of diabetes appears to be 
a less important factor than glycaemic control in 
forecasting progression from earlier to later 
stages of retinopathy (23). On the other hand, the 
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link between HbA1c levels and diabetic 
retinopathy is not conclusive because there are 
other variables that come into play. In our study, 
the patients treated with oral diabetic drug 
therapy had a significantly lower median 
concentration of HbA1c, without the presence of 
diabetic retinopathy (Figure 2A and B). 
Maintaining control of glucose and blood 
pressure lowers the risk of retinopathy 
progression and patients should be aware of the 
importance of maintaining good levels of 
glycosylated haemoglobin and blood pressure. 
Considering a higher prevalence of DM globally, 
family medicine doctors should improve 
additional educational programs in diabetic 
retinopathy screening because multiple 
workflow and systems-level barriers affect care 
providers and there is not enough time to follow 
all diagnostic features in everyday clinical 
practices (24). The study by Olafsdottir E et al. 
discusses the benefits of regular screening for 
diabetes mellitus and diabetic eye disease as 
the gold standard in preventing diabetic 
blindness. According to that study, the loss of 
vision from diabetic retinopathy is uncommon if 
regular screening is provided and subsequent 
hospital costs are also lower. The same idea has 
been confirmed in the study by Bandurska-
Stankiewicz E et al., who have confirmed that the 
incidence of vision loss due to diabetes is 
significantly lower in the countries which have 
introduced programs for preventing retinopathy 
than in those countries which do not have such 
programs (25, 26). While current evidence 
indicates that the association between the 
glucagon-like peptide-1 receptor agonists (GLP-
1RA), sodium-glucose cotransporter-2 (SGLT-2) 
inhibitors and dipeptidyl peptidase-4 (DPP-4i) 
inhibitors and the risk of DR remains uncertain in 
patients with T2DM, future studies should focus 
on such types of drugs, especially on the 
combinations and prevalence of DR, PDR and 
NPDR in large-scale, well-designed studies (27).  
Once retinopathy is present, the duration of 
diabetes appears to be a less important factor 
than glycaemic control in forecasting 
progression from earlier to later stages of 
retinopathy. In our study, there is a lack of 
information about the type of OAD and DR, so in 
future studies, we will pay more attention to the 
association of DR, new OAD and combinations of 
therapy. In addition, opportunities exist in 
leveraging team-based care approaches, 
patient self-management programs and 
emerging telemedicine imaging technologies. 
Conclusion 
Our study has confirmed the results of previous 
studies, namely that the risk of development and 
progression of diabetic retinopathy is closely 
associated with the type and duration of 
diabetes and HbA1c concentration. Also, we 
emphasise that there is still a pressing need for 
a better understanding of a new therapeutic 
modality, new tools for identifying high-risk 
patients and continued monitoring in order to 
intervene effectively before vision loss occurs. 
Further research is needed to identify and 
implement the best practices to increase 
diabetic eye screening rates in the long term. 
There is a lack of additional educational 
programs in primary health care of diabetic 
retinopathy screening and a lack of large-scale, 
well-designed studies of diabetic retinopathy 
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